[ad_1]
Bone minerals are the inorganic compounds of bone tissue that help strengthen bones with their plaque and globular structures. These minerals are formed from carbonated hydroxyapatite. Bone minerals are dynamic in living beings, it is continuously reabsorbed and built again in the process of bone remodeling. The bone functions as a calcium reservoir, from which calcium is continuously removed or stored as part of homeostasis. The metabolism of bone minerals refers to the maintenance of a sufficient concentration of inorganic ions in the blood serum, regardless of the metabolic activities of the muscle tissues. Hormones such as parathyroid hormone and calcitonin play a vital role in controlling muscle metabolic activities, these hormones are regulated by the neuroendocrine system and produced by the parathyroid and thyroid glands in the neck. The dysfunction of these glands results in a metabolic balance and creates problems of bone mineral metabolism. Metabolic bone disorders and mineral density are bone abnormalities caused by calcium, phosphorus, magnesium and vitamin D aberrations, which result in several reversible clinical disorders. These disorders are usually treatable if the underlined cause is treated with corrective treatment methods. These disorders are caused by genetic or metabolic dysfunctions in the body.
The global market for bone and mineral metabolism disorders continues to experience positive growth due to the increased prevalence of chronic kidney disease and metabolic dieses. According to the National Kidney Foundation (NKF), the prevalence of CKD in the United States is 13.5% in 2010. It is estimated that 10 million Americans over age 50 are afflicted with HIV. osteoporosis, while 34 million are at risk of developing bone disease. Other factors that determine the market include the aging of the population and obese patients. The presence of local and multinational players offering a wide range of products will help support the market for treatment of bone and mineral metabolism disorders during the forecast period. Increased awareness of the management of bone and mineral metabolism disorders among health professionals and improved access to diagnosis could have a positive impact on this market over the time period. However, increased management costs of co-morbidities, non-compliance with treatment protocols, and side effects associated with medications may hamper market growth in the treatment of bone and mineral metabolism disorders during the prediction
www.persistencemarketresearch.com/samples/12655
The global market for the treatment of bone metabolism disorders and mineral metabolism has been segmented according to the type of drug, the type of disease, the channel distribution and the region.
Based on the type of drug, the global market for treatment of bone and mineral metabolism disorders is segmented into: Bisphosphonates, estrogens, phosphate binders, non-calcium, non-metallic binder, metal-based binders, magnesium base, analogues and vitamin D supplements, calcimimetics agents, calcium and magnesium supplements; Based on the type of disease, the global market for bone mineral metabolism disorders is segmented into: osteomalacia, osteoporosis, osteopenia, rickets, mineral and bone diseases associated with chronic kidney disease (CKD-MBD), bone Paget, Osteogenesis imperfecta, Others; Based on the distribution channel, the global market for bone metabolism and mineralogy disorders is segmented as follows: hospital pharmacies, retail pharmacies, online pharmacies, pharmacies
The global market for the treatment of bone metabolism disorders and mineral undergoes market changes. Increased competition between local and multinational players has helped make the cost of treatment more economical. With the availability of a wide variety of products in various forms and strengths in the treatment of bone metabolism disorders and mineral metabolism, the market should change the dynamics of the market over a given period of time. Depending on the type of disease, sub-segments such as osteoporosis and rickets in the global market for treatment of bone and mineral metabolism disorders are expected to grow positively due to the increased prevalence of diseases in women and children postmenopausal areas. [19659002] Geographically, the market for the treatment of disorders of bone and mineral metabolism is segmented into regions namely. North America, Latin America, Europe, Asia-Pacific and Japan, Middle East and Africa. North America and Europe will remain key markets for the market for bone and mineral metabolism disorders due to the higher cost of products and the aging of the population in the region. The Asia-Pacific is expected to record positive growth due to the increase in the prevalence of metabolic diseases, stenting in children and a favorable population dynamics.
Visit For TOC @ https: //www.persistencemarketresearch.com/toc/12655
Market participants in the treatment of bone mineral metabolism include Merck & Co., Inc., F Hoffmann-La Roche Ltd., Novartis AG, Warner Chilcott LLC, Sanofi, Shire, AbbVie Inc., Amgen Inc., to name a few.
Messages:
4
Source link
